viatris glp-1 receptor agonist medications Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports GLP-1 receptor agonists | How
Description
The dual agonist approach represented by tirzepatide demonstrates that activating multiple complementary pathways produces superior results to targeting a single pathway, even when that single pathway works quite well on its own
The data supports this
Nat Med 2015;21:2736.PubMed 59
29 It significantly affects blood glucose levels by increasing insulin release or suppressing glucagon secretion and inhibits appetite via receptors in the ventral tegmental region, nucleus accumbens, and hypothalamus
Most patients find they diminish significantly after the first month
Unlike some medications where morning versus evening makes a pharmacological difference, weekly semaglutide injections are flexible
